How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals insiders completed 6 transactions totaling $589,430.56. Activity included 2 tax-related stock dispositions, 2 open market sales, and 2 stock awards (non-cash). View more ...